A to Z Health Guide 2007
The scientific bulletin of the year may be the stem-cell breakthrough. But 2007 provided a whole alphabet of big medical news. TIME's A-to-Z guide reviews them
—By Coco Masters, Alice Park, Carolyn Sayre, Tiffany Sharples, Alexandra Silver and Kate Stinchfield
The task of keeping diabetes in check has gotten harder. While rosiglitazone, GlaxoSmithKline's (GSK) Avandia, lowers blood-sugar levels, it also increases the risk of heart attack 42% and doubles the risk of heart failure, according to a study in the Journal of the American Medical Association. Other ongoing research, however, does not show such an increased risk. Even so, the FDA has issued a warning label alerting users to increased danger of heart attack, and Canadian officials have restricted the drug to those with hard-to-control blood sugar. GSK will issue a pamphlet explaining the warning and will begin a study next year to compare Avandia with other diabetes drugs.
View the full list for "A to Z Health Guide 2007"Latest Lists
Most Popular »
- Why Obama Has to Worry About Polls
- Israel vs. Hizballah: Drumbeats of War
- The Pentagon Prepares for a Missile Attack from 'Iran'
- Stalemate: How Obama's Iran Outreach Failed
- The '00s: Goodbye (at Last) to the Decade from Hell
- Benedict's Pope: Should Pius XII Become a Saint?
- Will Your Next Car be Made in India?
- Sony's Robot-Cam: Partying Without a Photographer
- Rehabilitating Joseph Stalin
- In Cleveland, Worker Co-Ops Look to a Spanish Model
- Rehabilitating Joseph Stalin
- New Job for Ex-Soviet Pilots: Arms Trafficking
- Dear President Obama: What North Korea Might Say
- Will Your Next Car be Made in India?
- Did Reid Make Health Reform Tougher Than It Had to Be?
- Why Obama Has to Worry About Polls
- Should Parents of Obese Kids Lose Custody?
- Benedict's Pope: Should Pius XII Become a Saint?
- Joe Klein's Annual Teddy Awards
- Slow Times At My 20th High School Reunion
RSS